|
1
|
Gorlick R and Khanna C: Osteosarcoma. J
Bone Miner Res. 25:683–691. 2010. View
Article : Google Scholar
|
|
2
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar
|
|
3
|
Negoro K, Yamano Y, Fushimi K, Saito K,
Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, Tanzawa H
and Fujita S: Establishment and characterization of a
cisplatin-resistant cell line, KB-R, derived from oral carcinoma
cell line, KB. Int J Oncol. 30:1325–1332. 2007.PubMed/NCBI
|
|
4
|
Chen X, Yang TT, Wang W, Sun HH, Ma BA, Li
CX, Ma Q, Yu Z and Fan QY: Establishment and characterization of
human osteosarcoma cell lines with different pulmonary metastatic
potentials. Cytotechnology. 61:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shibata K, Umezu T, Sakurai M, Kajiyama H,
Yamamoto E, Ino K, Nawa A and Kikkawa F: Establishment of
cisplatin-resistant ovarian yolk sac tumor cells and investigation
of the mechanism of cisplatin resistance using this cell line.
Gynecol Obstet Invest. 71:104–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: an evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asada N, Tsuchiya H, Ueda Y and Tomita K:
Establishment and characterization of an acquired
cisplatin-resistant subline in a human osteosarcoma cell line.
Anticancer Res. 18:1765–1768. 1998.PubMed/NCBI
|
|
9
|
Maraldi NM, Zini N, Santi S, Scotlandi K,
Serra M and Baldini N: P-glycoprotein subcellular localization and
cell morphotype in MDR1 gene-transfected human osteosarcoma cells.
Biol Cell. 91:17–28. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y
and Tsuneyoshi M: Establishment of new multidrug-resistant human
osteosarcoma cell lines. Oncol Rep. 7:859–866. 2000.PubMed/NCBI
|
|
11
|
Niu BH, Wang JJ, Xi Y and Ji XY: The
establishment and characterization of adriamycin-resistant cell
lines derived from Saos-2. Med Sci Monit. 16:BR184–BR192.
2010.PubMed/NCBI
|
|
12
|
Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo
KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis
of the EC109/CDDP multidrug-resistant esophageal squamous cell
carcinoma cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
|
|
13
|
Wang C, Guo LB, Ma JY, Li YM and Liu HM:
Establishment and characterization of a paclitaxel-resistant human
esophageal carcinoma cell line. Int J Oncol. 43:1607–1617.
2013.PubMed/NCBI
|
|
14
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakai W, Swisher EM, Karlan BY, Agarwal
MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ,
Couch FJ, Urban N and Taniguchi T: Secondary mutations as a
mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature.
451:1116–1120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bellmunt J, Paz-Ares L, Cuello M, Cecere
FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz
JJ, Taron M, Rosell R and Baselga J; Spanish Oncology Genitourinary
Group. Gene expression of ERCC1 as a novel prognostic marker in
advanced bladder cancer patients receiving cisplatin-based
chemotherapy. Ann Oncol. 18:522–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Li ZN, Du YJ, Li XQ, Bao QL and Chen
P: Expression of MRP1, BCRP, LRP, and ERCC1 in advanced
non-small-cell lung cancer: correlation with response to
chemotherapy and survival. Clin Lung Cancer. 10:414–421. 2009.
View Article : Google Scholar
|
|
19
|
Borst P, Evers R, Kool M and Wijnholds J:
A family of drug transporters: the multidrug resistance-associated
proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liedert B, Materna V, Schadendorf D,
Thomale J and Lage H: Overexpression of cMOAT (MRP2/ABCC2) is
associated with decreased formation of platinum-DNA adducts and
decreased G2-arrest in melanoma cells resistant to cisplatin. J
Invest Dermatol. 121:172–176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamasaki M, Makino T, Masuzawa T, Kurokawa
Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori
M and Doki Y: Role of multidrug resistance protein 2 (MRP2) in
chemoresistance and clinical outcome in oesophageal squamous cell
carcinoma. Br J Cancer. 104:707–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen HH and Kuo MT: Role of glutathione in
the regulation of cisplatin resistance in cancer chemotherapy. Met
Based Drugs. 2010:4309392010. View Article : Google Scholar
|
|
23
|
Lai GM, Moscow JA, Alvarez MJ, Fojo AT and
Bates SE: Contribution of glutathione and glutathione-dependent
enzymes in the reversal of adriamycin resistance in colon carcinoma
cell lines. Int J Cancer. 49:688–695. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sagawa Y, Fujitoh A, Nishi H, Ito H,
Yudate T and Isaka K: Establishment of three cisplatin-resistant
endometrial cancer cell lines using two methods of cisplatin
exposure. Tumor Biol. 32:399–408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishikawa T: The ATP-dependent glutathione
S-conjugate export pump. Trends Biochem Sci. 17:463–468. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tajeddine N, Galluzzi L, Kepp O, Hangen E,
Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami
N, Modjtahedi N, Harel-Bellan A and Kroemer G: Hierarchical
involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death.
Oncogene. 27:4221–4232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jain HV and Meyer-Hermann M: The molecular
basis of synergism between carboplatin and ABT-737 therapy
targeting ovarian carcinomas. Cancer Res. 71:705–715. 2011.
View Article : Google Scholar : PubMed/NCBI
|
